Asymmetric dimethylarginine (ADMA) modulates endothelial function - therapeutic implications

Böger RH , Bode-Böger SM , Frölich JC. The l-arginine-nitric oxide pathway: role in atherosclerosis and therapeutic implications. Atherosclerosis 1996; 127: 1-11.

Böger RH. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res 2003; 59: 824-833.

Vallance P , Leone A , Calver A , Collier J , Moncada S. Accumulation of an endogenous inhibitor of NO synthesis in chronic renal failure. Lancet 1992; 339: 572-575.

Böger RH , Bode-Böger SM , Szuba A et al. Asymmetric dimethylargi-nine: a novel risk factor for endothelial dysfunction. Its role in hyper-cholesterolemia. Circulation 1998; 98: 1842-1847.

Surdacki A , Nowicki M , Sandmann J et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetrical dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999; 33: 652-658.

Abbasi F , Asagami T , Cooke JP , et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001; 88: 1201-1203.

Stühlinger M , Abbasi F , Chu JW et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. J Am Med Assoc 2002; 287: 1420-1426.

Achan V , Broadhead M , Malaki M et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003; 23: 1455-1459.

Miyazaki H , Matsuoka H , Cooke JP. Endogenous nitric oxide synthase inhibitor. A novel marker of atherosclerosis. Circulation 1999; 99: 1141-1146.

Zoccali C , Benedetto FA , Maas R et al. Asymmetric dimethylarginine (ADMA), C-reactive protein, and carotid intima media-thickness in end-stage renal disease. J Am Soc Nephrol 2002; 13: 490-496.

Zoccali C , Bode-Böger SM , Mallamaci F et al. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase predicts mortality in end-stage renal disease (ESRD). Lancet 2001; 358: 2113-2117.

Valkonen VP , Päivä H , Salonen JT et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358: 2127-2128.

Laufs U , La F , Plutzky J , Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-1135.

Kaesemeyer WH , Caldwell RB , Huang J , Caldwell RW. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 1999; 33: 234-241.

Leung WH , Lau CP , Wong CK. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients. Lancet 1993; 341: 1496-1500.

Treasure CB , Klein JL , Weintraub WS et al. Beneficial effect of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332: 481-487.

Takemoto M , Liao JK. Pleiotropic effects of 3-hydroxy-3-methylgluta-ryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21: 1712-1719.

Vita JA , Yeung AC , Winniford M et al. Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease. Circulation 2000; 102: 846-851.

Van Venrooij FV , van de Ree MA , Bots ML , Stolk RP , Huisman MV , Banga JD. Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomised, double-blind, placebo-controlled trial. Diabetes Care 2002; 25: 1211-1216.

Janatuinen T , Laakso J , Laaksonen R et al. Plasma asymmetric dime-thylarginine modifies the effect of pravastatin on myocardial blood flow in young adults. Vasc Med 2003; 8: 185-189.

John S , Delles C , Jacobi J et al. Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin. J Am Coll Cardiol 2001; 37: 1351-1358.

Fathi R , Haluska B , Short L , Marwick TH. A randomised trial of aggressive lipid reduction for improvement of myocardial ischemia, symptom status, and vascular function in patients with coronary artery disease not amenable to intervention. Am J Med 2003; 114: 445-453.

Schwartz RG , Pearson TA , Kalaria VG et al. Prospective serial evaluation of myocardial perfusion and lipids during the first six months of pravastatin therapy: coronary artery disease regression single photon emission computed tomography monitoring trial. J Am Coll Cardiol 2003; 42: 600-610.

Lu TM , Ding YA , Lin SJ et al. Plasma levels of asymmetric dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J 2003; 24: 1912-1919.

Böger RH. When the endothelium cannot say ‘NO’ anymore. ADMA, and endogenous inhibitor of NO synthase, promotes cardiovascular disease. Eur Heart J 2003; 24: 1901-1902.

Böger RH , Bode-Böger SM , Tsao PS , Lin PS , Chan JR , Cooke JP. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol 2000; 36: 2287-2295.

Fickling SA , Leone AM , Nussey SS , Vallance P , Whitley GSJ. Synthesis of NG, NG dimethylarginine by human endothelial cells. Endothelium 1993; 1: 137-140.

Böger RH , Sydow K , Borlak J et al. LDL cholesterol upregulates synthesis of asymmetric dimethylarginine (ADMA) in human endothelial cells. Involvement of S-adenosylmethionine-dependentmethyltransferases. Circ Res 2000; 87: 99-105.